In this interview, Joop Arends discusses his thoughts on the future of diagnosis and management of hepatitis C, and also gives us his highlights from ECCMID.
Browsing: Viral > Hepatitis
In line with Hepatitis Awareness Month, we spoke to Marcus Dorner about his current research into the host–virus interactions in hepatitis B and C infection, their implications for vaccine development and more.
Researchers have demonstrated that both hepatitis B and hepatitis C infection are associated with an increased risk of Parkinson’s disease.
A new systematic evidence review has discovered that FDA-approved direct-acting antiviral regimens are effective against all genotypes of hepatitis C.
In this editorial the author examines the initiatives taken by Drugs for Neglected Diseases (DNDi) and Medicines Patent Pool (MPP) organizations to improve access to pan-genotypic hepatitis C treatment.
In this review the authors look into the potential use of pharmacogenomics in predisposing ribavirin-treated hepatitis C patients to anemia.